Abstract Number: 2341 • ACR Convergence 2025
Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. The PsA Impact of Disease-12 (PsAID-12) questionnaire is…Abstract Number: 1503 • ACR Convergence 2025
Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
Background/Purpose: Systemic Lupus Erythematosus (SLE) disease activity can affect the normal functioning of the patients. This functioning in various domains can be assessed using quality…Abstract Number: 1253 • ACR Convergence 2025
Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Background/Purpose: When treating patients with rheumatological conditions, building a strong physician-patient relationship plays an important role in determining disease outcomes. The Routine Assessment of Patient…Abstract Number: 0767 • ACR Convergence 2025
Quality of Life in Patients with Rheumatoid Arthritis with Foot and Ankle Involvement
Background/Purpose: Foot and ankle involvement in patients with rheumatoid arthritis is a common yet often underexplored and underrecognized manifestation. This can negatively affect patients' quality…Abstract Number: 2337 • ACR Convergence 2025
A Mediation Analysis of Tofacitinib’s Effects on SF-36: The Roles of Fatigue, Pain, Stiffness, and Mobility in Ankylosing Spondylitis
Background/Purpose: Mediation modeling is used to determine mechanisms underlying the relationship between independent and dependent variables via other explanatory variables (“mediators”). Fatigue, pain, and morning…Abstract Number: 1487 • ACR Convergence 2025
Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
Background/Purpose: To improve quality of life (QoL) in individuals with SLE, we developed the Whole Health Empowerment for Endotypes of Lupus (WHEEL) program—a 4-month, biweekly,…Abstract Number: 1248 • ACR Convergence 2025
Patient and Clinician Perception and Use of Complementary and Alternative (CAM) Medicine for Rheumatic Disease
Background/Purpose: Complementary and alternative medicine (CAM) use is increasingly prevalent among patients with rheumatic diseases, yet alignment between patient practices and clinician perspectives remains poorly…Abstract Number: 0730 • ACR Convergence 2025
Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
Background/Purpose: It is known that health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) is impaired. Categories of disease activity levels have been…Abstract Number: 2326 • ACR Convergence 2025
Impact of Regular Exercise, Mobility Impairment, and Obesity on Quality of Life in Patients with Axial Spondyloarthritis: A Cross-Sectional Analysis from the Brazilian Registry of Spondyloarthritis
Background/Purpose: Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease that impairs quality of life. While pharmacological treatment is central to axSpA management, non-pharmacological strategies are…Abstract Number: 1461 • ACR Convergence 2025
Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial
Background/Purpose: Axial spondyloarthritis (axSpA) is often associated with persistent pain despite effective anti-inflammatory treatment, substantially impacting patients' quality of life. Digital health applications (DiGAs) provide…Abstract Number: 0600 • ACR Convergence 2024
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL‑17F in addition to IL‑17A, has demonstrated sustained reductions in disease impact of PsA, assessed…Abstract Number: 1229 • ACR Convergence 2024
Frequency of Fibromyalgia Using Validated Measures in a Sample of Patients with Psoriatic Arthritis and Impact on Disease: A Cross-Sectional Multinational Study
Background/Purpose: Fibromyalgia (FM), a chronic pain disorder, is more prevalent in psoriatic arthritis (PsA) patients, impacting quality of life and potentially leading to unnecessary treatment escalation. Cultural factors may…Abstract Number: 2115 • ACR Convergence 2024
Clinical Impact of Acute Symptomatic Vertebral Fractures in the United States: An Observational Study
Background/Purpose: To characterize pain status (frequency, severity, persistency) and effect on activities of daily living (ADLs) in patients with symptomatic vertebral fractures (VF).Methods: This was…Abstract Number: PP05 • ACR Convergence 2024
Reunion with Forgotten Relationships and Memories
Background/Purpose: Paediatric rheumatic diseases are complex experiences for children. For children whose language skills are still undeveloped, it is difficult for them to put their…Abstract Number: 0614 • ACR Convergence 2024
Bridging the Gap Between Patient’s Perception on Quality of Life and Disease Activity and Damage in Systemic Lupus Erythematous Patient
Background/Purpose: Improving quality of life (QoL) is one of the key targets when treating systemic lupus erythematosus (SLE) patients. The Lupus impact Tracker (LIT) is…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 30
- Next Page »
